BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE. METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards. RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitiv-ity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research. CONCLUSION: These standards provide a person -cen-tred, consensus-based approach to minimise the impact of AE TB treatment.

Clinical standards for the management of adverse effects during treatment for TB / Singh, K. P.; Carvalho, A. C. C.; Centis, R.; D´Ambrosio, L.; Migliori, G. B.; Mpagama, S. G.; Nguyen, B. C.; Aarnoutse, R. E.; Aleksa, A.; van Altena, R.; Bhavani, P. K.; Bolhuis, M. S.; Borisov, S.; van´t Boveneind-Vrubleuskaya, N.; Bruchfeld, J.; Caminero, J. A.; Carvalho, I.; Cho, J. G.; Davies Forsman, L.; Dedicoat, M.; Dheda, K.; Dooley, K.; Furin, J.; García-García, J. M.; Garcia-Prats, A.; Hesseling, A. C.; Heysell, S. K.; Hu, Y.; Kim, H. Y.; Manga, S.; Marais, B. J.; Margineanu, I.; Märtson, A-G.; Munoz Torrico, M.; Nataprawira, H. M.; Nunes, E.; Ong, C. W. M.; Otto-Knapp, R.; Palmero, D. J.; Peloquin, C. A.; Rendon, A.; Rossato Silva, D.; Ruslami, R.; Saktiawati, A. M. I.; Santoso, P.; Schaaf, H. S.; Seaworth, B.; Simonsson, U. S. H.; Singla, R.; Skrahina, A.; Solovic, I.; Srivastava, S.; Stocker, S. L.; Sturkenboom, M. G. G.; Svensson, E. M.; Tadolini, M.; Thomas, T. A.; Tiberi, S.; Trubiano, J.; Udwadia, Z. F.; Verhage, A. R.; Vu, D. H.; Akkerman, O. W.; Alffenaar, J. W. C.; Denholm, J. T.. - In: INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. - ISSN 1027-3719. - ELETTRONICO. - 27:7(2023), pp. 506-519. [10.5588/ijtld.23.0078]

Clinical standards for the management of adverse effects during treatment for TB

Tadolini, M.;
2023

Abstract

BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE. METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards. RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitiv-ity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research. CONCLUSION: These standards provide a person -cen-tred, consensus-based approach to minimise the impact of AE TB treatment.
2023
Clinical standards for the management of adverse effects during treatment for TB / Singh, K. P.; Carvalho, A. C. C.; Centis, R.; D´Ambrosio, L.; Migliori, G. B.; Mpagama, S. G.; Nguyen, B. C.; Aarnoutse, R. E.; Aleksa, A.; van Altena, R.; Bhavani, P. K.; Bolhuis, M. S.; Borisov, S.; van´t Boveneind-Vrubleuskaya, N.; Bruchfeld, J.; Caminero, J. A.; Carvalho, I.; Cho, J. G.; Davies Forsman, L.; Dedicoat, M.; Dheda, K.; Dooley, K.; Furin, J.; García-García, J. M.; Garcia-Prats, A.; Hesseling, A. C.; Heysell, S. K.; Hu, Y.; Kim, H. Y.; Manga, S.; Marais, B. J.; Margineanu, I.; Märtson, A-G.; Munoz Torrico, M.; Nataprawira, H. M.; Nunes, E.; Ong, C. W. M.; Otto-Knapp, R.; Palmero, D. J.; Peloquin, C. A.; Rendon, A.; Rossato Silva, D.; Ruslami, R.; Saktiawati, A. M. I.; Santoso, P.; Schaaf, H. S.; Seaworth, B.; Simonsson, U. S. H.; Singla, R.; Skrahina, A.; Solovic, I.; Srivastava, S.; Stocker, S. L.; Sturkenboom, M. G. G.; Svensson, E. M.; Tadolini, M.; Thomas, T. A.; Tiberi, S.; Trubiano, J.; Udwadia, Z. F.; Verhage, A. R.; Vu, D. H.; Akkerman, O. W.; Alffenaar, J. W. C.; Denholm, J. T.. - In: INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE. - ISSN 1027-3719. - ELETTRONICO. - 27:7(2023), pp. 506-519. [10.5588/ijtld.23.0078]
Singh, K. P.; Carvalho, A. C. C.; Centis, R.; D´Ambrosio, L.; Migliori, G. B.; Mpagama, S. G.; Nguyen, B. C.; Aarnoutse, R. E.; Aleksa, A.; van Altena, R.; Bhavani, P. K.; Bolhuis, M. S.; Borisov, S.; van´t Boveneind-Vrubleuskaya, N.; Bruchfeld, J.; Caminero, J. A.; Carvalho, I.; Cho, J. G.; Davies Forsman, L.; Dedicoat, M.; Dheda, K.; Dooley, K.; Furin, J.; García-García, J. M.; Garcia-Prats, A.; Hesseling, A. C.; Heysell, S. K.; Hu, Y.; Kim, H. Y.; Manga, S.; Marais, B. J.; Margineanu, I.; Märtson, A-G.; Munoz Torrico, M.; Nataprawira, H. M.; Nunes, E.; Ong, C. W. M.; Otto-Knapp, R.; Palmero, D. J.; Peloquin, C. A.; Rendon, A.; Rossato Silva, D.; Ruslami, R.; Saktiawati, A. M. I.; Santoso, P.; Schaaf, H. S.; Seaworth, B.; Simonsson, U. S. H.; Singla, R.; Skrahina, A.; Solovic, I.; Srivastava, S.; Stocker, S. L.; Sturkenboom, M. G. G.; Svensson, E. M.; Tadolini, M.; Thomas, T. A.; Tiberi, S.; Trubiano, J.; Udwadia, Z. F.; Verhage, A. R.; Vu, D. H.; Akkerman, O. W.; Alffenaar, J. W. C.; Denholm, J. T.
File in questo prodotto:
File Dimensione Formato  
s4.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 152.44 kB
Formato Adobe PDF
152.44 kB Adobe PDF Visualizza/Apri
iutld_ijtld_23.0078_supplementarydata1.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 124.46 kB
Formato Adobe PDF
124.46 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/966125
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact